Search clinical trials for: safety and efficacy study with PF-04991532

Total 480672 results

Pfizer

Completed

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Taiwan, Slovakia, Mexico, Canada, Hungary
Pfizer

Completed

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

Diabetes, Type 2

Canada, United States, Korea, Republic of, Taiwan, Mexico, Hungary, Slovakia
Pfizer

Completed

A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus

United States
Pfizer

Completed

Single Dose Study of PF-04991532 in Healthy Subjects

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus

United States
Danish Head and Neck Cancer Group

Recruiting

DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. (DAHANCA30)

Hypoxia | Head and Neck Squamous Cell Carcinoma | Radiotherapy | Hypoxic Modification | Gene Profile, Gene Signature

Denmark
Pfizer

Completed

Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus

United States
Pfizer

Completed

A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Japan
Pfizer

Completed

Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532

Healthy | Type 2 Diabetes Mellitus

United States
Pfizer

Completed

Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532

Healthy

United States
Olympus Biotech Corporation

Completed

The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study (TRANS-North)

Diabetic Foot Ulcer of Neuropathic Origin

Belgium, Germany, Poland, Croatia, Bulgaria, Denmark, Slovakia, Hungary, Netherlands, Sweden
Pfizer

Completed

Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532

Healthy

United States
Children's Hospital of Philadelphia
National Library of Medicine (NLM)

Completed

Comprehensive Clinical Decision Support (CDS) for the Primary Care of Premature Infants (PreemieCDS)

Prematurity

United States
Pfizer

Completed

Single Dose Study Of The Effect Of Cyclosporine On The Pharmacokinetics Of PF-04991532 In Health Volunteers

Healthy | Drug Interaction

Belgium
Prince of Songkla University

Active, not recruiting

Gastric Volume After Ingestion of Carbohydrate Drink vs Water in Obese Volunteers

Obesity | Gastric Emptying

Thailand
Assiut University

Not yet recruiting

Intrapartum Ultrasonography in Evaluation of the Progress of Labor

Progress pf Labor
MTI University

Unknown

Triceps Taping on Elbow Flexion Tightness in Extended Erb's Palsy

Deformity Flexion

Egypt
Pfizer

Withdrawn

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Pfizer

Completed

Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers

Healthy

Singapore
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
Karen-Lise Garm Spindler
Zealand University Hospital; Vejle Hospital

Recruiting

OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer (OPTIMISE)

Colorectal Cancer | Metastatic Cancer

Denmark
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Shire

Completed

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease (OPERA)

Crohn's Disease

Korea, Republic of, United States, Spain, Japan, Serbia, Germany, Belgium, Netherlands, Poland, Austria, Bulgaria, Canada, France, Norway, Slovakia, South Africa
Pfizer

Completed

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD)

United States
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Pfizer

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B (BENEGENE-2)

Hemophilia B

Germany, United Kingdom, Canada, Australia, Taiwan, Japan, France, Turkey, Korea, Republic of, United States, Brazil, Greece, Saudi Arabia, Sweden
Quark Pharmaceuticals
Pfizer

Terminated

Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema (DEGAS)

Diabetes Complications | Diabetic Retinopathy

United States, United Kingdom, Italy, Israel, Germany, Peru, Denmark, India
Pfizer

Completed

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Diabetes Mellitus, Type 2

Taiwan, United States, Hungary, Canada, Slovakia, India, Bulgaria
Telavant, Inc.
Pfizer

Withdrawn

Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease

Crohn Disease
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
HaEmek Medical Center, Israel

Unknown

Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients

Herpes Zoster

Israel
Pfizer

Withdrawn

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Healthy
Pfizer

Terminated

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

Huntington's Disease

United States, Germany, Poland, United Kingdom, Canada
Pfizer

Withdrawn

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects (A7881006)

Respiratory Tract Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma, Bronchial
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Pfizer

Completed

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Healthy | Chronic Rhinosinusitis With Nasal Polyps | Atopic Dermatitis

United States
Pfizer

Completed

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Healthy

United States
Pfizer

Completed

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Canada
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

Obesity

United States, Taiwan, Canada, Japan
Pfizer

Completed

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Psoriasis

Canada, United States, Japan, Poland
Telavant, Inc.
Pfizer

Completed

Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

Colitis, Ulcerative

United States, Korea, Republic of, Belgium, Italy, Netherlands, Poland
Fusion Pharma LLC
Data Matrix Solutions; OCT Rus, LLC; Skolkovo Innovation Center

Unknown

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myeloid Leukemia

Russian Federation
Pfizer

Completed

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada, Chile, Czechia
Pfizer

Withdrawn

Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome

Tourette's Syndrome

United States
Pfizer

Terminated

Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo

Schizophrenia

United States
Pfizer

Completed

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

Huntington's Disease

United States, Germany, United Kingdom, Canada, Poland

3

Subscribe